Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IPSC 
Century Therapeutics Inc (IPSC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IPSC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.25
1 Year Target Price $4.25
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.88% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.35M USD | Price to earnings Ratio - | 1Y Target Price 4.25 |
Price to earnings Ratio - | 1Y Target Price 4.25 | ||
Volume (30-day avg) 6 | Beta 1.79 | 52 Weeks Range 0.34 - 1.83 | Updated Date 10/14/2025 |
52 Weeks Range 0.34 - 1.83 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.4% | Operating Margin (TTM) -25.11% |
Management Effectiveness
Return on Assets (TTM) -5.11% | Return on Equity (TTM) -10.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -61372785 | Price to Sales(TTM) 0.42 |
Enterprise Value -61372785 | Price to Sales(TTM) 0.42 | ||
Enterprise Value to Revenue 1.96 | Enterprise Value to EBITDA 0.08 | Shares Outstanding 86389098 | Shares Floating 45209143 |
Shares Outstanding 86389098 | Shares Floating 45209143 | ||
Percent Insiders 27.57 | Percent Institutions 41.88 |
Upturn AI SWOT
Century Therapeutics Inc
Company Overview
History and Background
Century Therapeutics was founded in 2018, focused on developing allogeneic cell therapies for cancer. It has progressed through preclinical stages, and initial clinical trials have commenced.
Core Business Areas
- Allogeneic Cell Therapy Development: Developing off-the-shelf, engineered cell therapies designed to overcome the limitations of autologous therapies. Focus on iPSC-derived NK and T cells.
Leadership and Structure
Lino Ramirez (CEO), Luis Borges (CSO). Operates with a functional structure focused on R&D, clinical development, and manufacturing.
Top Products and Market Share
Key Offerings
- CNT-4003: Allogeneic CAR-iNK cell therapy targeting CD19+ malignancies. Currently in Phase 1 clinical trials. Market share is negligible as it is pre-commercial. Competitors include Kite Pharma (GILD) and Novartis (NVS) with their autologous therapies and companies developing other allogeneic approaches.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and personalized medicine. Competition is intense, with many companies pursuing autologous and allogeneic approaches.
Positioning
Century is focused on allogeneic therapies, aiming for scalability and accessibility advantages over autologous therapies. This positions them as a potential disruptor in the cell therapy space.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach USD 82.68 billion by 2030. Century is focused on capturing a share of this market with its allogeneic cell therapies.
Upturn SWOT Analysis
Strengths
- Allogeneic platform technology
- Experienced management team
- Strong intellectual property position
- iPSC-derived cell therapy expertise
Weaknesses
- Early stage of development
- High cash burn rate
- Clinical trial risks
- Reliance on third-party manufacturing
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in cell engineering technology
- Positive clinical trial results
Threats
- Competition from established cell therapy companies
- Regulatory hurdles
- Manufacturing challenges
- Unforeseen clinical trial outcomes
Competitors and Market Share
Key Competitors
- GILD
- NVS
- CRIS
- BLUE
Competitive Landscape
Century's allogeneic approach provides a potential advantage in terms of scalability and cost compared to autologous therapies. However, it faces challenges in achieving similar efficacy levels.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expanding R&D activities and progressing clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships. Analyst estimates vary, but project significant revenue potential if therapies are approved.
Recent Initiatives: Focus on advancing lead programs through clinical trials and expanding the pipeline with new cell therapy candidates.
Summary
Century Therapeutics is a clinical-stage biotechnology company focused on allogeneic cell therapies with significant potential. The company's technology offers a possible advantage over autologous methods, but it comes with significant risk associated with clinical trials and financial performance. A strong cash position offers a runway, but ongoing expenses are a challenge as the company matures. Century Therapeutics needs to look out for competition from established cell therapy companies and potential setbacks in clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Century Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-06-18 | President, CEO & Chairman Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 140 | Website https://www.centurytx.com |
Full time employees 140 | Website https://www.centurytx.com | ||
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.